Biography
Elizabeth Ross is an associate in Weil’s Antitrust group. Her practice focuses on U.S. and global regulatory approval for mergers and acquisitions, government investigations, and general antitrust counseling. She has experience across a wide range of industries including oil and gas, pharmaceuticals, insurance, retail, private equity, and asset management
Elizabeth received her J.D. from the Northwestern Pritzker School of Law, where she served as an Executive Editor of the Northwestern Journal of Law and Social Policy. She earned her B.A., summa cum laude in International Relations from Tufts University, where she also graduated Phi Beta Kappa. Prior to joining Weil, Elizabeth served as a summer law clerk at the US Federal Trade Commission in the Bureau of Consumer Protection for the Midwest Region.
Elizabeth’s recent public experience includes serving on Weil teams representing:
- ChampionX Corporation in its pending $7.8 billion sale to SLB, and its pending sale of US Synthetic Corporation to LongRange Capital
- WTW in the $632 million sale of its TRANZACT direct-to-consumer insurance distribution business to GTCR.
- Sign In Solutions, a portfolio company of PSG Equity, in its acquisition of U.K.-based SmartSpace Software Plc
- Walgreens Boots Alliance, Inc. in its acquisition of 120 retail pharmacies from Brookshire Grocery Company
- NJOY, Inc., in its $2.75 billion sale to Altria Group, Inc.
- Regeneron Pharmaceuticals in connection with monopolization and other claims against Novartis relating to actions taken to prevent competition from Regeneron’s PFS version of Eylea.
- NEOGEN Corporation in its $5.3 billion combination with the Food Safety business of 3M.
- Brookfield Asset Management Inc. in its approximately $4.8 billion acquisition of a 61.2% stake in Oaktree Capital Group, LLC
- Blackstone Capital Partners and its portfolio company, PSAV, a global AV and event technology services provider, in its acquisition of Encore Event Technologies